Sumitomo companies to set up joint pharma plants

9 November 2001

Sumitomo Chemical and Sumitomo Pharmaceuticals have reached agreement toset up joint drug manufacturing plants due to growing demand for the latter's products. The plants will be based at the former's Oita prefecture site and are expected to be operational in spring 2003.

Sumitomo Chemical has been supplying Sumitomo Pharmaceuticals with drug raw materials from the Oita manufacturing site for some time, which the latter has processed into finished medicine such as antianxiolitics and angina drugs at its Ibaraki prefecture plant. By bringing the whole process to a single site, the companies foresee added efficiencies.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight